These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 2253202

  • 1. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
    Jansen G, Schornagel JH, Westerhof GR, Rijksen G, Newell DR, Jackman AL.
    Cancer Res; 1990 Dec 01; 50(23):7544-8. PubMed ID: 2253202
    [Abstract] [Full Text] [Related]

  • 2. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.
    Westerhof GR, Jansen G, van Emmerik N, Kathmann I, Rijksen G, Jackman AL, Schornagel JH.
    Cancer Res; 1991 Oct 15; 51(20):5507-13. PubMed ID: 1655252
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR.
    Cancer Res; 1991 Oct 15; 51(20):5579-86. PubMed ID: 1913676
    [Abstract] [Full Text] [Related]

  • 7. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ, Estlin EJ, Taylor GA, Aherne GW, Hardcastle A, McGuire JJ, Calvete JA, Lunec J, Pearson AD, Newell DR.
    Clin Cancer Res; 1999 Sep 15; 5(9):2548-58. PubMed ID: 10499632
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
    Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT.
    Clin Cancer Res; 1997 Jun 15; 3(6):911-21. PubMed ID: 9815766
    [Abstract] [Full Text] [Related]

  • 10. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS, Galivan J, Wright JE, Rosowsky A.
    Mol Pharmacol; 1994 Apr 15; 45(4):783-91. PubMed ID: 7514264
    [Abstract] [Full Text] [Related]

  • 11. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
    Jackman AL, Newell DR, Gibson W, Jodrell DI, Taylor GA, Bishop JA, Hughes LR, Calvert AH.
    Biochem Pharmacol; 1991 Oct 24; 42(10):1885-95. PubMed ID: 1741766
    [Abstract] [Full Text] [Related]

  • 12. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL, Taylor GA, O'Connor BM, Bishop JA, Moran RG, Calvert AH.
    Cancer Res; 1990 Sep 01; 50(17):5212-8. PubMed ID: 2386929
    [Abstract] [Full Text] [Related]

  • 13. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM.
    Mol Pharmacol; 1995 Sep 01; 48(3):459-71. PubMed ID: 7565626
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism.
    McGuire JJ, Haile WH, Yeh CC.
    Cancer Res; 2006 Apr 01; 66(7):3836-44. PubMed ID: 16585211
    [Abstract] [Full Text] [Related]

  • 16. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
    Miyachi H, Takemura Y, Kobayashi H, Ando Y.
    Jpn J Cancer Res; 1997 Sep 01; 88(9):900-6. PubMed ID: 9369939
    [Abstract] [Full Text] [Related]

  • 17. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
    Jansen G, Mauritz RM, Assaraf YG, Sprecher H, Drori S, Kathmann I, Westerhof GR, Priest DG, Bunni M, Pinedo HM, Schornagel JH, Peters GJ.
    Adv Enzyme Regul; 1997 Sep 01; 37():59-76. PubMed ID: 9381986
    [Abstract] [Full Text] [Related]

  • 18. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL, Alison DL, Calvert AH, Harrap KR.
    Cancer Res; 1986 Jun 01; 46(6):2810-5. PubMed ID: 2938731
    [Abstract] [Full Text] [Related]

  • 19. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
    Diddens H, Niethammer D, Jackson RC.
    Cancer Res; 1983 Nov 01; 43(11):5286-92. PubMed ID: 6225514
    [Abstract] [Full Text] [Related]

  • 20. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ.
    Clin Cancer Res; 1999 Mar 01; 5(3):643-54. PubMed ID: 10100718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.